Rindopepimut
- Generic Name
- Rindopepimut
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 1108208-65-6
- Unique Ingredient Identifier
- K3L4X0501F
- Background
Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases. The vaccine consists of the EGFRv3-specific peptide (a 13-amino acid mutant vIII epitope) conjugated to the non-specific immunomodulator keyhole limpet hemocyanin (KLH). The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015.
- Indication
Investigated for use/treatment in brain cancer.
- Associated Conditions
- -
- Associated Therapies
- -
Glioblastoma Clinical Trials: Current Landscape and Trends
Recurrent glioblastoma trials often exclude patients based on prior treatment specifics, potentially unfairly limiting participation. Recent trends show more trials for newly diagnosed cases, with broader eligibility criteria. However, overly restrictive criteria and reliance on single-arm phase II studies hinder progress, underscoring the need for more inclusive and randomized trials to improve outcomes.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath